Test Price
2,800 AED✅ Home Collection Available
OBSL1 Gene (Three M Syndrome Type 2) Genetic Test in UAE
Executive Summary & Core Metrics
This DHA-licensed next-generation sequencing (NGS) test detects pathogenic variants in the OBSL1 gene, confirming a diagnosis of Three M syndrome type 2. The test is performed under strict regulatory oversight with integrated clinical genetics expertise.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM–11 PM).
- Clinical Guidance: Telephonic post-test interpretation by a DHA-licensed consultant medical geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This NGS test analyzes the OBSL1 gene with full exon coverage and copy-number variation detection, providing definitive molecular diagnosis of Three M syndrome type 2. The analysis is conducted in our DHA-licensed laboratory using validated protocols and ACMG-classified variant interpretation. Results are correlated with clinical dysmorphology and family history to deliver actionable diagnostic guidance.
| Feature | Our Test (DNA Labs UAE) | Closest Alternative (Overseas Lab) |
|---|---|---|
| Technology | NGS with full gene coverage & copy‑number analysis | Sanger sequencing of selected exons only |
| Reporting | Clinically curated, ACMG‑classified, 3‑4 weeks TAT | Technical raw data, up to 10 weeks |
| UAE Compliance | Full PDPL & DHA data residency requirements, genetic counselling included | May not meet local data residency laws |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasise that the OBSL1 gene test must be interpreted alongside a detailed dysmorphology evaluation and three-generational family history. The NGS report is a powerful diagnostic tool, but a negative result does not exclude Three M syndrome if clinical suspicion remains high. Pre- and post-test genetic counselling is essential for accurate variant classification and recurrence-risk calculation.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Advisory: Genetic Testing and Medication Management
This genetic test does not provide guidance on medication management. Do not alter or discontinue any prescribed therapy based on test results without consulting your treating physician. Always follow your doctor's advice regarding medications and supplements.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Test not performed on minors without legal guardian consent (Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Exclusion: Inadequate sample (degraded DNA, insufficient volume) requires recollection.
- Emergency Red Flag: If the patient develops acute respiratory distress, cyanosis, severe feeding intolerance, or signs of increased intracranial pressure, seek immediate emergency care – genetic testing is not a substitute for acute clinical management.
Patient FAQ & Clinical Guidance
1. What does the OBSL1 gene test detect and how is it used in UAE paediatric care?
This test identifies disease-causing mutations in the OBSL1 gene that confirm Three M syndrome type 2, a rare growth disorder characterised by prenatal and postnatal growth retardation, distinctive facial features, and skeletal anomalies. UAE paediatricians and neonatologists integrate the results with clinical and radiological findings to establish an accurate diagnosis, guide management, and offer genetic counselling for affected families.
2. How long do results take and who will explain them?
Final reports are delivered within 3–4 weeks after sample receipt and are interpreted by a DHA-licensed consultant medical geneticist during a dedicated telephonic consultation. The session covers variant classification, recurrence risk, and recommended follow-up.
3. Is home sample collection available and how is privacy protected?
Yes, we offer VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection across all emirates (available daily from 8 AM to 11 PM). All genetic data is handled strictly under the UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and stored in DHA-compliant secure servers with anonymised reporting.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed under the regulatory framework of the Dubai Health Authority (DHA) and complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring patient genetic data privacy, consent, and secure storage.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing digital health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishing standards for clinical consent and patient safety.
Data residency is maintained within UAE borders, with anonymised reporting for research purposes only upon explicit patient consent.
Clinical & Logistical Metadata
| Test Name | OBSL1 Gene (Three M Syndrome Type 2) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood or extracted DNA (FTA card accepted) |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage and copy-number analysis |
| ICD-10-CM Code | Q87.1 (Congenital malformation syndromes predominantly associated with short stature) |
| LOINC Code | 81208-7 (Gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians